98 related articles for article (PubMed ID: 29548844)
1. High-throughput cytotoxicity and antigen-binding assay for screening small bispecific antibodies without purification.
Sugiyama A; Umetsu M; Nakazawa H; Niide T; Asano R; Hattori T; Kumagai I
J Biosci Bioeng; 2018 Aug; 126(2):153-161. PubMed ID: 29548844
[TBL] [Abstract][Full Text] [Related]
2. A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.
Sugiyama A; Umetsu M; Nakazawa H; Niide T; Onodera T; Hosokawa K; Hattori S; Asano R; Kumagai I
Sci Rep; 2017 Jun; 7(1):2862. PubMed ID: 28588218
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
4. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. Structural diversity and flexibility of diabodies.
Kwon NY; Kim Y; Lee JO
Methods; 2019 Feb; 154():136-142. PubMed ID: 30261312
[TBL] [Abstract][Full Text] [Related]
7. Construction of a diabody (small recombinant bispecific antibody) using a refolding system.
Takemura S; Asano R; Tsumoto K; Ebara S; Sakurai N; Katayose Y; Kodama H; Yoshida H; Suzuki M; Imai K; Matsuno S; Kudo T; Kumagai I
Protein Eng; 2000 Aug; 13(8):583-8. PubMed ID: 10964988
[TBL] [Abstract][Full Text] [Related]
8. Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.
Wei L; Dongmei F; Ming Y; Ruizan S; Yan Y; Linlin J; Cihui Y; Shuangjing L; Min W; Jianxiang W; Dongsheng X
Cell Oncol (Dordr); 2012 Dec; 35(6):423-34. PubMed ID: 23055339
[TBL] [Abstract][Full Text] [Related]
9. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy.
Yuan Q; Liang Q; Sun Z; Yuan X; Hou W; Wang Y; Wang H; Yu M
Oncoimmunology; 2021; 10(1):1914954. PubMed ID: 34350059
[TBL] [Abstract][Full Text] [Related]
10. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
12. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
13. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput Generation of Bispecific Binding Proteins by Sortase A-Mediated Coupling for Direct Functional Screening in Cell Culture.
Andres F; Schwill M; Boersma YL; Plückthun A
Mol Cancer Ther; 2020 Apr; 19(4):1080-1088. PubMed ID: 31871271
[TBL] [Abstract][Full Text] [Related]
15. Retargeting serum immunoglobulin with bispecific diabodies.
Holliger P; Wing M; Pound JD; Bohlen H; Winter G
Nat Biotechnol; 1997 Jul; 15(7):632-6. PubMed ID: 9219264
[TBL] [Abstract][Full Text] [Related]
16. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
17. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies.
Giese G; Williams A; Rodriguez M; Persson J
Biotechnol Prog; 2018 Mar; 34(2):397-404. PubMed ID: 29193902
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
20. In vitro selection of bispecific diabody fragments using covalent bicistronic DNA display.
Nakayama M; Komiya S; Fujiwara K; Horisawa K; Doi N
Biochem Biophys Res Commun; 2016 Sep; 478(2):606-11. PubMed ID: 27473655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
